NEWS

 

Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M

MONTREAL, QC, Canada – March 14 th,

Laurent Pharmaceuticals Inc. (the “Company”), today announced that it has reached an agreement to receive an additional US$ 2 million commitment from US-based Cystic Fibrosis Foundation to further support the upcoming Phase 2 clinical study aimed at demonstrating the safety and efficacy of the Company’s lead compound LAU-7b in adult patients with cystic fibrosis (CF). This new award is in addition to the US$ 3 million development award already committed by the CF Foundation to the Company.

Read more ...

Laurent Pharmaceuticals Receives US$ 3M Development Award From Cystic Fibrosis Foundation Therapeutics

First Canadian Company To Obtain CFFT Therapeutics Development Award 

MONTREAL, QC, Canada – July 26th, 2016

Laurent Pharmaceuticals Inc. (the “Company”), a clinical stage orphan drug company, today announced it has received a Therapeutics Development Award of up to US$3 million from US-based Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The award will help support the Phase 2 clinical trial of the Company’s lead drug candidate LAU-7b in adult patients with cystic fibrosis (“CF”).

Read more ...

Events

Laurent Pharmaceuticals to participate at RESI on MaRS, April 10th 2018, Toronto, Canada

Laurent Pharmaceuticals to participate at the Biotech Showcase, January 8-10th 2018, San Francisco, CA, USA